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Summary
Tumors escape from immune surveillance by producing the immunosuppressive cytokine TGF-β. However, the mechanism
by which TGF-β inhibits T cell-mediated tumor clearance in vivo is unknown. We demonstrate that TGF-β acts on cytotoxic
T lymphocytes (CTLs) to specifically inhibit the expression of five cytolytic gene products—namely, perforin, granzyme A,
granzyme B, Fas ligand, and interferon γ—which are collectively responsible for CTL-mediated tumor cytotoxicity. Repres-
sion of granzyme B and interferon-g involves binding of TGF-β-activated Smad and ATF1 transcription factors to their
promoter regions, indicating direct and selective regulation by the TGF-β/Smad pathway. Neutralization of systemic
TGF-β in mice enables tumor clearance with restoration of cytotoxic gene expression in antigen-specific CTLs in vivo. We
suggest that TGF-β suppresses CTL function in vivo through an anticytotoxic program of transcriptional repression.S I G N I F I C A N C E
The TGF-β pathway promotes cancer progression by concomitantly enhancing tumor metastases while inhibiting the host immune
response. While much emphasis has been placed on understanding the paradoxical impact of TGF-β on the tumor itself, relatively
little is known about the molecular effects of TGF-β on the immune response in vivo. Here we demonstrate that systemic neutralization
of TGF-β activity in mice restores expression of a distinct cytotoxic gene program in CD8+ T cells, which promotes antigen-specific
tumor clearance in vivo. Current cancer therapies are designed to target the TGF-β signaling pathway primarily in the tumor. We
propose that therapies that also counteract the immunosuppressive effects of TGF-β and incorporate restoration of the host immune
response may help achieve tumor eradication.Introduction
Malfunctions of the cytokine TGF-β contribute to three aspects
of tumor progression, namely, loss of growth inhibitory control,
gain of metastagenicity, and evasion of immune surveillance
(reviewed in Akhurst and Derynck [2001], Derynck et al. [2001],
Siegel and Massagué [2003]). During tumor progression, can-
cer cells frequently acquire resistance to the profound growth-
inhibitory action of TGF-β. This may occur either by mutations
that inactivate the TGF-β receptors or the Smad signal trans-
ducers, or by selective loss of downstream cytostatic, dif-
ferentiative or apoptotic gene responses. In the latter case, the
remaining TGF-β gene responses may foster invasion and me-
tastasis. But in all cases, a loss of growth inhibitory control
may allow tumor cells to use TGF-β for evasion of immune sur-
veillance.
TGF-β has sweeping inhibitory effects on the immune sys-
tem, negatively affecting many immune cell types and func-
tions (Gorelik and Flavell, 2002; Letterio, 2000). TGF-β1-defi-
cient mice present spontaneously activated T cells and die of
massive inflammation in vital organs (Diebold et al., 1995).
Similarly, Smad3-deficient mice develop spontaneously acti-
vated T cells that are resistant to TGF-β-mediated growth inhi-
bition (McKarns et al., 2004; Yang et al., 1999). TGF-β controls
T cell homeostasis by directly inhibiting both T cell proliferationCANCER CELL : NOVEMBER 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIEand activation and by also inhibiting presentation of antigens on
antigen-presenting cells (reviewed in Gorelik and Flavell [2002]).
Of all the mechanisms employed by tumor cells to avoid
clearance, production or activation of TGF-β is considered one
of the most potent (Wojtowicz-Praga, 2003). This has been
demonstrated in various mouse tumor models (Torre-Amione
et al., 1990; Won et al., 1999). When challenged with TGF-β-
producing tumors, mice whose T cells have been made resis-
tant to TGF-β by expression of a dominant-negative TGF-β
receptor transgene are able to mount an immune response,
eliminate the tumor burden, and survive (Gorelik and Flavell,
2000, 2001). Adoptive transfer experiments have demonstrated
that the CD8+ T cell compartment is centrally responsible for
this tumor clearance process (Gorelik and Flavell, 2001). Inhibi-
tion of TGF-β signaling in the CD8+ T cell compartment may
therefore suffice to restore tumor immunity. However, little is
known about the molecular mechanisms mediating TGF-β sup-
pression of antitumor immunity by T cells.
Activated CTLs, which are predominantly responsible for an-
tigen-specific clearance of tumor cells, typically utilize two ma-
jor contact-dependent pathways to kill target cells (reviewed in
Russell and Ley [2002]). One is the granule exocytosis path-
way. When an activated CTL recognizes a tumor cell, the
membrane-pore-forming protein, perforin, mediates delivery of
the apoptosis-inducing proteases Granzyme A (GzmA) and/orR INC. DOI 10.1016/j.ccr.2005.10.012 369
A R T I C L EGranzyme B (GzmB) into the target cell. The mechanisms of
GzmA- and GzmB-induced apoptosis, as defined by cleavage
of their respective intracellular substrates, are quite distinct
(Lieberman and Fan, 2003; Trapani and Smyth, 2002). The sec-
ond contact-dependent mechanism, the Fas-Fas ligand (FasL)
pathway, activates target cell death via cytochrome c release
and activation of caspases (Russell and Ley, 2002). Addition-
ally, soluble mediators including TNFα and interferon γ (IFNγ)
are secreted by CTLs to induce target cell cytotoxicity.
TGF-β signaling involves its binding to a serine/threonine ki-
nase receptor complex formed by receptor types I and II, fol-
lowed by receptor-mediated phosphorylation of Smad2 and
Smad3 (reviewed in Shi and Massagué [2003]; Massagué et al.
[2000]). Thus activated, Smad2 and -3 then bind to Smad4.
The Smad2/3-Smad4 complex associates with other DNA
binding proteins, forming different complexes of defined target
gene specificity and transcriptional activation or repression ac-
tivity. For example, a TGF-β cytostatic gene response program
has been delineated in epithelial cells, and the cofactors that
enable Smad complexes to target and regulate these genes
have been identified (Chen et al., 2002; Kang et al., 2003;
Seoane et al., 2002; Siegel et al., 2003).
The molecular mechanisms suppressing T cell activation in
response to TGF-β have yet to be elucidated. To address this
problem, we employed a mouse tumor model in which neutral-
ization of systemic TGF-β activity results in tumor clearance.
Using transcriptomic profiling, we identified a striking suppres-
sion by TGF-β of factors that constitute the CTL cytotoxic pro-
gram—perforin, GzmA, GzmB, FasL, and IFNγ. At least two of
these genes, GzmB and IFNg, are directly recognized by
Smads and ATF1 in response to TGF-β, indicating that the CTL
cytotoxic program is directly targeted by the Smad pathway.
Furthermore, we demonstrate that neutralization of TGF-β re-
stores expression of these genes in tumor-specific CD8+ T
cells in vivo, leading to tumor clearance. These results suggest
that TGF-β suppresses CD8+ T cell cytotoxicity in vivo through
repression of a distinct program of cytotoxic gene responses.
Results
Neutralization of systemic TGF-β restores T cell
cytotoxicity and tumor clearance in vivo
Various tumor models have been employed to establish the
role of TGF-β in promoting tumor growth in vivo. One such
tumor model is the EL4 thymoma cells, which secrete TGF-β1
and may additionally coerce the production or activation of
TGF-β from host tissue sources (Gorelik and Flavell, 2001; Won
et al., 1999). Intraperitoneal injection of EL4 thymoma cells into
mice leads to tumor burden within 7–10 days and death in ap-
proximately 3 weeks. Previous studies have indicated that sys-
temic neutralization of TGF-β in vivo or inhibition of TGF-β sig-
naling specifically in the T cell compartment restores tumor cell
clearance (Gorelik and Flavell, 2001; Won et al., 1999). Using
two approaches to abrogate the immunosuppressive activity of
TGF-β, we analyzed this tumor model to determine how TGF-β
mediates immune evasion in vivo. First, to determine whether
the tumor cells were the major source of TGF-β, we generated
an EL4-derivative cell line (EL4-shTGFβ1) that stably expresses370a short hairpin RNAi targeting TGF-β1. Expression of TGF-β1
in EL4-shTGFβ1 cells is decreased by 85% compared to par-
ental EL4 (Figure 1A). Expression of TGF-β2 and TGF-β3 was
not detectable in EL4 cells (data not shown). Second, EL4 cells
were infected with the empty vector (EL4-pRS cells) or with a
retroviral construct encoding soluble TGF-β type II receptor
(TβR-II) extracellular domain to neutralize tumor-derived and
surrounding sources of TGF-β (Figure 1A). All three cell lines
were injected into cohorts of syngeneic mice, and tumor devel-
opment and survival were monitored. Mice injected with EL4-pRS
developed significant tumor burdens, with 80% of the mice hav-
ing to be sacrificed between 16 and 20 days (Figure 1B). While
there was a delay in tumor development, 75% of the mice in-
jected with EL4-shTGF-β1 tumors ultimately succumbed to the
tumor burden, (p value = 1.0). In contrast, only 20% of the mice
injected with EL4 cells expressing soluble TβR-II died (EL4-solu-
ble TβR-II; p value = 0.008; Figure 1B). Therefore, neutralization
of systemic TGF-β, but not reduction of tumor-derived TGF-β,
could restore tumor-free survival in mice.
To determine the effect of these TGF-β-blocking strategies
on T cell-mediated tumor lysis, CD8+ T cells were assessed
for cytotoxic activity against EL4 tumor cells, using a standard
51Cr-release assay (Heusel et al., 1994). When cultured with
labeled EL4 tumor cells directly following purification, only
CD8+ T cells derived from EL4-soluble TβR-II-injected mice
were able to kill EL4 tumor cell targets, in a dose-dependent
manner (Figure 1C). These CD8+ T cells were capable of rec-
ognizing and killing both EL4 and EL4-soluble TβR-II tumor
cells in vitro, indicating that the immune response was directed
against the tumor cell itself and not the soluble receptor (Figure
1D). Even at the highest T cell-to-tumor ratio (100:1), CD8+ T
cells derived from mice injected with either EL4-pRS or EL4-
shTGF-β1 tumor cells were unable to kill target cells. Charac-
terization of the CD8+ T cells by flow cytometry did not show
significant differences in CD8+ T cell number, cell size, or ex-
pression of the activation marker CD69 among the three co-
horts of mice (data not shown). In addition, TGF-β treatment of
EL4 tumor cells in vitro did not result in tumor cell growth arrest
or apoptosis, indicating that the effects of TGF-β in vivo are
most likely not on the tumor itself (data not shown). Therefore,
in this model system, systemic neutralization of TGF-β in vivo
is required for specifically restoring T cell-mediated cytotoxic-
ity, leading to tumor clearance.
TGF-β represses a cytotoxic gene program
in T lymphocytes
To identify TGF-β-target genes in T cells that would favor tumor
evasion in vivo, we performed transcriptomic profiling of freshly
isolated primary mouse T lymphocytes activated ex vivo. T
cells become activated upon antigen recognition and signaling
through the T cell receptor-CD3 complex, with concomitant
CD28 costimulation. To mimic T cell receptor engagement
in vitro, T cells were stimulated with anti-CD3 plus anti-CD28
antibodies, in the presence or absence of TGF-β. RNA from
these cells was used to probe Affymetrix U74Av2 mouse ge-
nome microarrays, which had 12,422 probe sets containing
9198 unique genes and 430 ESTs. The expression of approxi-
mately 69 known genes and 18 ESTs was increased, and 35
known genes and four ESTs decreased (>2.0 fold change, p =
0.001) by TGF-β under these conditions (Figure 2A and seeCANCER CELL : NOVEMBER 2005
A R T I C L EFigure 1. Neutralization of systemic TGF-β in vivo
restores T cell cytotoxicity
A: EL4 tumor cells were infected with either
empty retroviral vector (pRS), with retroviruses
expressing short-hairpin RNAs against TGF-β1
(shTGF-β1), or encoding a soluble form of TβR-II.
Northern analysis was performed for TbR-II and
Tgf-b1. Soluble TβR-II expression was detected in
cell culture supernatants by immunoblot.
B: Syngeneic mice were injected i.p. with 2.5 ×
106 EL4-pRS, EL4-shTGF-β1, or EL4-soluble TβR-II
cells and observed for tumor growth and sur-
vival. P values were obtained using Fisher’s ex-
act test on two independent experiments.
C and D: On day 10 postinoculation, CD8+ T
cells were purified from each cohort of EL4-
injected mice and cultured for 3 hr with 51Cr-
labeled EL4 (C) or EL4-pRS and EL4-soluble TβR-II
tumor cells (D) at an E:T ratio of 100.
Each point was performed in triplicate, with the
mean percent 51Cr release and standard de-
viation shown here.Table S1 in the Supplemental Data available with this article
online). These responses included induction of the cell adhe-
sion receptor integrin αE and the TGF-β-negative feedback
genes smad7 and ski, and downregulation of the growth-pro-
moting transcription factor c-myc. These TGF-β responses are
typical in other cell types and serve here as a reference. Five
additional downregulated genes, perforin, granzyme A (GzmA),
granzyme B (GzmB), interferon-g (IFNg), and Fas ligand (FasL)
(highlighted in yellow, Figure 2A), were of particular interest be-
cause all are mediators of CTL-mediated cytotoxicity and con-
tribute to tumor clearance (Russell and Ley, 2002). While the
perforin-Gzm pathway is the major effector arm of CTL-medi-
ated cytotoxicity, the Fas-FasL pathway and IFNγ secretion
have also been implicated in tumor regression (Lee and Fergu-
son, 2003; Shankaran et al., 2001; Street et al., 2001; Trapani
and Smyth, 2002). Repression of these genes would explain
the suppressive effects of TGF-β specifically on CTLs.
Upon T cell stimulation, expression of these five genes indi-
cates differentiation of the naive CD8+ T cell population into
activated CTLs (Schluns and Leofrancois, 2003). To determine
whether TGF-β inhibited overall CD8+ T cell activation, we as-
sessed expression of various cell surface receptors and activa-
tion markers. Using FACS analysis, we observed that TGF-β
did not affect the proportion of primary T cells expressing the
TCR CD3 chain or the coreceptors CD4 and CD8 (Figure 2B).
More importantly, TGF-β treatment did not alter expression of
the activation markers, CD69 or CD44hi, indicating that the
CD8+ T cells were comparably activated (summarized in Figure
2B). Loss of CD62L, a naive T cell marker that is downregulated
upon T cell activation, was also not altered by TGF-β treatment.
While there was a slight decrease in expression of the IL-2 re-
ceptor α chain (CD25) expression, this suggests an effect on
T cell proliferation rather than T cell activation. Therefore, the
decrease in cytotoxic gene expression was not due to selectiveCANCER CELL : NOVEMBER 2005depletion of CD8+ cells from the T cell population or inhibition
of overall CD8+ T cell activation.
Inhibition of perforin, GzmA, GzmB, IFNγ, and FasL expres-
sion by TGF-β at the mRNA level was verified in purified CD8+
T cells (Figure 2C). We also analyzed protein expression by in-
tracellular FACS staining and confirmed that TGF-β inhibits ex-
pression of all five genes to varying degrees (Figure 2D). TGF-β
decreased both the proportion of CD8+ T cells expressing
GzmB and the level of GzmB expression (Figure 2D). The num-
ber of CD8+ T cells expressing high levels of IFNγ was also
decreased, while the number of CD4+ T cells that expressed
IFNγ at all was low (Figure 2D and data not shown), which cor-
responded to the levels of secreted IFNγ (Figure 2E). Activation
of T cells using anti-CD3 and anti-CD28 antibodies leads to
relatively low levels of GzmA, perforin, and FasL, compared to
levels of GzmB and IFNγ. However, TGF-β clearly inhibited the
expression of perforin, GzmA, and FasL in these cells (Figure
2D). Thus, five genes constituting the cytotoxic gene program
in CD8+ T cells are selectively repressed by TGF-β.
We next assessed the ability of TGF-β to inhibit the expres-
sion of these genes in response to intact tumor stimulation of
T cells in vitro. Spleen cells were cultured with the irradiated
tumor cell line, P815, in mixed lymphocyte reactions, in the
presence or absence of TGF-β, to generate tumor-specific
CTLs (MLR-CTLs) (Heusel et al., 1994). Following activation
with P815 tumor cells, expression of Perforin, GzmA, GzmB,
and FasL, but not IFNg, could be detected by Northern analy-
sis, and continuous treatment with TGF-β inhibited the expres-
sion of these genes (Figure 3A). Protein immunoblotting analy-
sis confirmed that perforin, GzmA, and GzmB production was
repressed in these cells (Figure 3A). Compared to antibody-
mediated activation of primary T cells, the activation mediated
by P815 tumor cells causes a robust induction of GzmA, com-
parable to GzmB, but TGF-β inhibited the expression of both371
A R T I C L EFigure 2. Identification of the TGF-β-regulated cytotoxic gene program in primary T lymphocytes
A: CD4+/CD8+ T cells were purified from mouse spleens and activated with 0.25 g/ml anti-CD3 plus 1 g/ml anti-CD28 antibodies in the presence or
absence of 100 pM TGF-β. Transcriptomic profiling was performed with the mouse U74Av2 Affymetrix microarrays. The plot shows the fold change gene
expression +TGF-β/−TGF-β. Genes of interest are labeled in yellow (see also Table S1).
B: Primary T cells were activated, as in (A), for 48 hr and analyzed for expression of cell surface markers cells by flow cytometry.
C: Primary CD8+ T cells were activated as in (A), and Northern analysis was performed with the indicated probes.
D: Primary T cells were activated as in (A) for 48 hr and stained for the surface receptors CD4 and CD8, followed by intracellular staining with the indicated
fluorescent antibodies. CD8+ T cells were analyzed for expression of Perforin, GzmA, GzmB, IFNγ, or FasL.
E: CD4+, CD8+, or bulk T cells were purified and activated as in (A) for 48 hr. Supernatants were analyzed in triplicate for IFNγ secretion by ELISA.granzymes. The inhibitory effect of TGF-β on FasL expression
was reproducible but small (Figure 3A).
MLR-CTLs were then assayed for their ability to kill tumor
cells in vitro. TGF-β inhibited the proliferation of MLR-CTLs by
40%–50% (data not shown). However, even after normaliza-
tion of effector-to-tumor cell ratios, MLR-CTLs treated with
TGF-β were approximately 3-fold less effective in rapid (3 hr)
tumor cell lysis, as measured by 51Cr release (Figure 3B, top
left panel). MLR-CTLs can also induce DNA fragmentation
(125IdUR release) in the target cell, which was also found to
be abrogated by TGF-β, compared to unmodified MLR-CTLs
(Figure 3B, top right panel). Even at later time points (6 hr), we
found that TGF-β-treated MLR-CTLs were still unable to induce
equivalent 51Cr or 125IdUR release from tumor cell targets (Fig-
ure 3B, bottom). Collectively, these observations indicate that
in vitro TGF-β inhibits the ability of CTLs to kill tumor cells via
the GzmA-perforin, GzmB-perforin, and Fas-FasL pathways,
correlating with the ability of TGF-β to inhibit expression of
these genes.372TGF-β represses the cytotoxic gene program
independently of growth inhibition
Another significant effect of TGF-β on T cells is the inhibition
of interleukin-2 (IL-2) expression (McKarns et al., 2004), as
confirmed, both at the mRNA level (Figure 2A; Northern analy-
sis data not shown) and the secreted protein level (Figure 4A).
This effect correlates with T cell growth arrest (Figure 4B). As
IL-2 is induced upon T cell activation to stimulate T cell prolifer-
ation, we wondered whether the decrease in the overall cyto-
toxic gene expression by TGF-β was secondary to inhibition of
T cell proliferation. To address this question, we used recombi-
nant IL-2 (rIL-2) as the mitogenic stimulus in primary T cells,
thus bypassing the need for T cell receptor activation and auto-
crine IL-2 production. Since naive T cells only express the low-
affinity IL-2 receptor β and γ chains but not the high-affinity α
chain, we chose a range of rIL-2 concentrations that would
achieve proliferation comparable to T cells stimulated through
their T cell receptor. TGF-β only partially inhibited rIL-2-driven
T cell proliferation (Figure 4C), whereas it profoundly inhibitedCANCER CELL : NOVEMBER 2005
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sion to inhibit CTL-induced tumor cell cytotoxic-
ity in vitro
A: Primary MLR-CTLs were generated by stimula-
tion with irradiated P815 tumor cells for 5 days,
with or without TGF-β, and Northern and immu-
noblot analyses were performed for the indi-
cated genes.
B: Primary MLR-CTLs, minus and plus TGF-β, were
incubated with 51Cr or 125IdUR-labeled P815 tar-
get cells for 2 or 6 hr at various effector-to-target
cell ratios. 125IdUR release is a measurement of
DNA fragmentation, and 51Cr release is a mea-
surement of tumor cell lysis.
Each point was performed in triplicate, with the
mean percent 51Cr and percent 125IdUR release
and their respective standard deviations shown
here.the expression of Perforin, GzmA, GzmB, and IFNg in these
cells (Figure 4D).
To better separate the antimitogenic and anticytotoxic ef-
fects of TGF-β, we analyzed these effects in the IL-2-depen-
dent, CD8+ T cell line CTLL-2. These cells express high levels
of CD25 and the activation marker CD69, indicating that the
cells are in an activated state and can respond readily to IL-2
stimulation. Using multiple rIL-2 concentrations, we found that
TGF-β inhibits CTLL-2 proliferation after 24 hr of concurrent IL-2
and TGF-β treatment (Figure 4E). In contrast, expression of
both perforin and GzmB is rapidly repressed within 4 hr of TGF-β
treatment (Figure 4F). Repression of GzmA by TGF-β in these
cells was not observed within this time frame, and IFNγ expres-
sion was not detectable (data not shown). Thus, while IL-2 is
critical for both T cell proliferation and cytotoxic gene expres-
sion, TGF-β can directly and rapidly inhibit expression of the
cytotoxic gene program, downstream of IL-2.
Direct Smad-ATF1 binding to GzmB
and IFNg promoter regions
Having identified multiple cytotoxic genes that are critical TGF-β
targets, we next wanted to determine whether these genes are
direct targets of the TGF-β-activated Smad pathway. Focusing
on TGF-β-mediated repression of GzmB, we cloned 3 kb of the
mouse GzmB upstream region in front of a luciferase reporter
gene and performed reporter assays in CTLL-2 cells (Figure
5A). Promoter deletion analysis mapped the TGF-β-responsive
region at position −885/−794 (Figures 5A and 5B). Inspection of
this 92 bp region revealed binding sites for transcription factors
AML1α, ATF1/CREB, and Oct1/GATA1 in proximity to potential
Smad binding elements (Figure 5B). Mutational analysis re-
vealed that the ATF1/CREB site was required for TGF-β-
induced repression in this assay system (Figure 5C).
To determine whether GzmB repression required new protein
synthesis, CTLL-2 cells were pretreated with cycloheximide
(CHX) prior to TGF-β treatment. In the presence of CHX, TGF-β
was no longer able to repress GzmB, unlike c-Myc repression,CANCER CELL : NOVEMBER 2005which does not require new protein synthesis (Figure 5D; Chen
et al., 2002). When we analyzed ATF1 and CREB expression,
we found that both genes were induced by TGF-β, even in the
presence of CHX (Figure 5D). The ability of TGF-β to induce
expression of transcription factors that subsequently function
as Smad partners to regulate other target genes is a phenome-
non that has been previously described in other TGF-β-regu-
lated processes (Massagué et al., 2005). In epithelial cells,
TGF-β elevates expression of another ATF family member,
ATF3, in a first-wave response, which then cooperates with the
Smads to repress Id1 expression (Kang et al., 2003).
To establish that a TGF-β-activated Smad complex binds di-
rectly to the GzmB promoter in vivo, we performed chromatin
immunoprecipitation (ChIP) analyses in primary T cells acti-
vated in the presence or absence of TGF-β (Figure 5E). TGF-β
induced the binding of Smad2/3 over the −930/−585 region of
the GzmB promoter in primary T cells (Figure 5F). In addition,
both ATF1 and CREB bound to this same region within the
GzmB promoter in a TGF-β-inducible manner (Figure 5E).
ATF1 has also been implicated in the repression of IFNγ dur-
ing differentiation of CD4+ Th2 cells (Penix et al., 1996). Upon
examination of the IFNγ proximal promoter (−300/+4), we no-
ticed two potential ATF1 binding sites near a Smad binding
element (Figure 5F), suggesting that TGF-β may utilize the
same mechanism to regulate expression of this cytotoxic gene.
ChIP assays in primary T cells demonstrated inducible binding
of ATF1 and Smad2/3, but not CREB, to the IFNγ promoter in
response to TGF-β (Figure 5E). Binding was not detected on
the β-actin promoter, which served as a negative control.
To determine the necessity of ATF1 and CREB, as well as the
Smads, for TGF-β-mediated GzmB repression, we performed
transient knockdown experiments using RNAi-mediated tech-
nology. CTLL-2 cells were transfected using siRNA oligonucle-
otides against GFP (siGFP) as a control or oligonucleotides
specific for ATF1 and CREB, which demonstrated a 80% and
75% loss of expression of these proteins, respectively (Figure
5G). Treatment of cells with TGF-β demonstrated that, with re-373
A R T I C L EFigure 4. TGF-β directly represses cytotoxic gene expression, independent of growth inhibition
CD4+/CD8+ T cells were activated with anti-CD3 plus various concentrations of anti-CD28 antibodies. IL-2 secretion was measured by ELISA (A), and
proliferation was measured by 125IdUR incorporation (B). (C) Primary T cells were stimulated with rIL-2, in the presence of absence of TGF-β, for 48 hr, and
growth inhibition was measured via 125IdUR incorporation. (D) Northern analysis was performed for the indicated genes in primary T cells activated with
1.0 g/ml rIL-2 for 24 hr. (E) CTLL-2 cells were stimulated with rIL-2, and proliferation was measured after 24 hr. (F) CTLL-2 cells were stimulated with 0.4 ng/
ml rIL-2, and Northern analysis was performed after 2 or 4 hr of TGF-β treatment with the indicated probes.duced levels of ATF1 and CREB, TGF-β was not as effective in
repressing GzmB, compared to control transfected oligonucle-
otides (46% versus 20%, Figure 5G). As a control, loss of ATF1
and CREB did not affect cMyc repression (Figure 5G). Finally,
we also coordinately knocked down expression of both Smad2
and Smad3 in CTLL-2 cells (approximately 75% for each, Fig-
ure 5H) and found that, in the absence of Smad2 and 3, TGF-
β could not repress expression of GzmB or perforin, while loss
of Smad3 alone had little effect (Figure 5H). While the detailed
mechanism of GzmB and IFNγ repression by Smad, ATF1, and
CREB remains to be defined, the present results provide evi-
dence that TGF-β targets these promoters in T cells via Smad
transcription factors. The direct nature of this interaction is
consistent with a selective inhibition of the CTL cytotoxic pro-
gram by TGF-β.
IL-2 restores TGF-β-suppressed T cell proliferation
and cytotoxic gene expression
We next investigated whether we could rescue expression of
the cytotoxic gene program and/or T cell proliferation following
TGF-β treatment. We compared the effects of two members of
the common cytokine receptor γ chain (γc) family: IL-2, be-
cause it induces cytotoxic gene expression and proliferation in
naive T cells, and IL-15, because it specifically regulates CD8+
T cell proliferation and the generation of effector memory cells
(Schluns and Leofrancois, 2003). Primary T cells were activated
in the presence or absence of TGF-β for 36 hr and then washed
and recultured in either fresh media alone (untreated), in media
plus IL-2, or in media plus IL-15 for another 36 hr (Figure 6A).
Although T cells were growth inhibited by TGF-β treatment (re-
fer to Figure 3B), removal of TGF-β and reculturing cells in me-374dia alone restored equivalent proliferation levels (Figure 6B).
Both IL-2 and IL-15 could restore comparable proliferation in
both TGF-β-treated and -untreated cells, although IL-2 was a
more potent growth stimulator (Figure 6B). IL-2 increased the
proportion of CD8+ T cells by 7%–10%, while IL-15 increased
it only 3%, irrespective of pretreatment with TGF-β (Figure 6C).
Neither cytokine significantly altered the proportion of CD4+
T cells. IL-15 also did not stimulate IL-2 secretion under any
conditions assayed here (data not shown).
We next analyzed expression of the cytotoxic effectors
GzmB and IFNγ to determine whether IL-2 or IL-15 could res-
cue their expression in TGF-β-treated CD8+ T cells. IL-2 in-
duced significant IFNγ expression in both activated T cell pop-
ulations, despite lower basal levels in TGF-β-pretreated cells,
while IL-15 did not induce IFNγ secretion (Figure 6D). The ma-
jority of activated T cells demonstrated significant GzmB ex-
pression, and reculturing with IL-2 or IL-15 had little effect (Fig-
ure 6E, left panel). In contrast, T cells activated in the presence
of TGF-β had lower basal levels of GzmB expression, which
could be rescued with IL-2 treatment but not with IL-15 (Figure
6E, right panel). Although only 27% of TGF-β-treated cells ex-
press GzmB, IL-2 increased the percentage to 91.2%, compa-
rable to levels in T cells that had not received TGF-β (Figure
6E, left panel). In sum, IL-2 can rescue T cell proliferation and
GzmB and IFNγ expression in T cells that were previously ex-
posed to TGF-β, whereas IL-15 can partially restore T cell pro-
liferation but not expression of cytotoxic genes.
TGF-β neutralization restores cytotoxic gene expression
in antigen-specific T cells in vivo
We have shown that TGF-β represses a distinct cytotoxic gene
program, which inhibits the overall ability of CD8+ T cells to killCANCER CELL : NOVEMBER 2005
A R T I C L EFigure 5. TGF-β-mediated repression of GzmB and IFNγ involves ATF1 and Smads 2/3 binding to both promoters in vivo
A: Full-length (3.0 kb) mouse GzmB promoter and sequential deletion constructs were cloned upstream of luciferase reporter constructs and delivered
into CTLL-2 cells via nucleofection (Amaxa). Luciferase activity was measured following 20 hr of TGF-β treatment. Each point was performed in triplicate
with mean Luc/renilla values plotted with their standard deviations.
B: Schematic of transcription factor binding sites within the −885/−794 mGzmB promoter.
C: Mutations were generated within the ATF1/CREB, Oct1/GATA1, or AML1α sites of the GzmB −885/+74 promoter, and luciferase assays were performed
as in (A).
D: CTLL-2 cells were pretreated with CHX prior to treatment with TGF-β for 4 hr. Northern analysis was then performed for the indicated genes.
E: ChIPs for GzmB, IFNg, and β-actin were performed using the indicated antibodies on primary T cells, activated in the presence or absence of TGF-β.
F: Alignment of GzmB and IFNg promoters, showing ATF1/CREB binding sites.
G and H: Knockdown of ATF1 and CREB (G) or Smad2 and Smad3 (H) was performed using transient transfection of siRNA oligonucleotides into CTLL-2
cells. siRNA oligonucleotides against GFP were used as control. Posttransfection (48 hr), cells were treated with TGF-β for 3 hr and RNA was harvested for
Northern analysis. Depletion of ATF1 and CREB mRNA levels in (G) is shown by Northern blot analysis. Depletion of Smad3 alone or Smad2 and Smad3 is
shown by Western blot analysis using Stat5a as a negative control. The amount of protein cell lysate (g) is indicated.tumor cells in vitro. However, we wanted to determine if TGF-β
affects expression of these cytotoxic effectors in vivo. Since in
vivo T cells respond to unique antigens displayed on the tumor
cell surface, we employed an antigen-specific tumor model to
identify which genes are restored in antigen-specific CD8+ T
cells by neutralization of TGF-β. We used the EL4 thymoma
subline (E.G7), which has been engineered to express the oval-
bumin antigen (OVA). SIINFEKL has been identified as the
dominant OVA peptide presented in the context of MHC class
I H-2Kb on the tumor cell surface (Gorelik and Flavell, 2001;
Makki et al., 2002). The majority of T cells reacting to EL4-OVA
tumor cells will recognize SIINFEKL as the antigenic tumor
peptide. To determine whether neutralization of TGF-β alters
the quantity and/or quality of antigen-reactive T cells in vivo,
we engineered EL4-OVA cells to express the soluble TβR-II
trap (Figure 7A). CD8+ T cells that recognize this tumor antigenCANCER CELL : NOVEMBER 2005can be identified using flow cytotmetry plus fluorescently la-
beled tetramers of recombinant H-2Kb molecules loaded with
the SIINFEKL peptide (Altman et al., 1996; Appay and Row-
land-Jones, 2002). Once identified, these T cells could be fur-
ther analyzed for cytotoxic effector expression using intra-
cellular staining (as in Figure 2). Mice were injected with either
EL4-OVA cells, EL4-OVA-soluble TβR-II cells, or the original
EL4-pRS cells as a negative control since they do not express
the OVA antigen. Spleen cells harvested 10 days later demon-
strated that the percentages of CD4+ and CD8+ T cells were
equivalent in mice injected with the EL4-OVA cell lines, indicat-
ing that there was no skewing of the T cell populations in vivo
(Figure 7B). In addition, the activation markers CD69 and CD44
were comparably expressed, and downregulation of CD62L
was observed in the spleens of all three groups as compared
to naive CD8+ T cells (Figures 7C and 7D and data not shown).375
A R T I C L EFigure 6. IL-2 rescues both T cell proliferation and cytotoxic gene expression following TGF-β treatment
A: T cells were activated in the presence or absence of TGF-β for 36 hr, washed extensively, and then recultured in media alone (untreated) plus rIL-2 or
plus rIL-15 for another 36 hr.
B–E: Proliferation (125IdUR incorporation) (B) expansion of CD4+ and CD8+ T cells (C), IFNγ secretion (D), and intracellular GzmB staining (E) were analyzed
in untreated T cells or T cells cultured with rIL2 or rIL-15, as described in (A). Mean CPMs with standard deviations from triplicate samples (B) and mean
concentrations with standard deviations from samples in triplicate (D) are shown here.Since comparable numbers of T cells were activated, either
directly or indirectly, by the tumor challenge, we conclude that
TGF-β does not alter the activation profile of OVA-specific
CD8+ T cells in vivo.
To determine whether there was an increase in the pro-
portion of antigen-specific T cells that develop when TGF-β is
neutralized in vivo, we next analyzed the proportion of CD8+,
tetramer-positive T cells. Analysis of spleen cells derived from
EL4-pRS-injected mice demonstrated background levels of
tetramer staining (0.3%; green lines, Figure 7E). When back-
ground tetramer staining was subtracted, the proportion of tet-
ramer-positive (i.e., antigen-specific) T cells that developed in
the presence of TGF-β was very low (0.2% ± 0.04%; blue
lines). This proportion is consistent with previous reports from
EL4 tumor-inoculated mice (Gorelik and Flavell, 2001). In con-
trast, expression of soluble TβR-II in these tumors increased
the number of antigen-specific T cells 4- to 5-fold compared
to EL4-OVA-injected mice (1.1% ± 0.3% versus 0.2% ±
0.04%; red lines, Figure 7E). In general, the number of tetra-
mer-positive T cells that develop in response to tumors or
pathogens in vivo is approximately 1% of the population (Alt-
man et al., 1996). Therefore, TGF-β inhibits antigen-specific T
cell expansion, and neutralization of systemic TGF-β restores
their development.376Based on these results, we sought to determine whether
in vivo neutralization of TGF-β could restore expression of the
same cytotoxic effectors that were identified as TGF-β target
genes in vitro. Combining surface staining of tetramer-positive
T cells with intracellular staining, we quantitated the fraction of
cells expressing either perforin, GzmA, GzmB, IFNγ, or FasL.
We found that neutralization of TGF-β in vivo augmented the
expression of perforin, GzmA, GzmB, and IFNγ (1.9- to 3-fold
increase) but not FasL, compared to mice injected with EL4-
OVA tumor cells (Figures 7E and 7F). Similar results in gene
expression were obtained in bulk CD8+ T cells derived from
mice injected with EL4-soluble TβR-II tumor cells (data not
shown). Thus, inhibition of TGF-β in vivo not only increases the
proportion of T cells that can respond to the tumor but also
restores the activities of the perforin-gzm pathway and IFNγ
secretion for tumor clearance.
Discussion
Selective and direct inhibition of the T cell cytotoxic
gene responses by TGF-β
During tumor progression, production of TGF-β leads to es-
cape from immune surveillance in vivo (Akhurst and Derynck,
2001; Derynck et al., 2001; Siegel et al., 2003). Since identifica-CANCER CELL : NOVEMBER 2005
A R T I C L EFigure 7. Neutralization of TGF-β restores expression of perforin, GzmA, GzmB, and IFNγ in antigen-specific T cells in vivo
A: Expression of TGF-β1 and soluble TβR-II in EL4-OVA tumor cells was determined by Northern analysis.
B–D: On day 10 postinjection, spleen cells were harvested from EL4-pRS (green lines), EL4-OVA (red lines), or EL4-OVA-soluble TβR-II (blue lines)-injected mice
and analyzed for the number of T cells expressing CD4 or CD8 (B) or the activation markers CD44 and CD62L (C) via flow cytometry and quantitated (D).
E and F: Spleen cells were stained with H-2Kb SIINFEKL-specific, PE-conjugated tetramers plus CD8 antibodies and analyzed by flow cytometry. The percent-
ages represent live, tetramer-specific, CD8+ T cells with a subtracted background of tetramer-reactive T cells from EL4-pRS-injected mice. Following
tetramer staining, intracellular staining was performed using indicated antibodies and analyzed. The percentage of tetramer-specific T cells expressing
perforin, GzmA, GzmB, IFNγ, or FasL is quantitated among the EL4-tumor cell lines. One representative experiment is shown. Experiments were repeated at
least three times, and the mean expression level of each gene with the standard error is plotted (F).tion of the relevant T cell gene responses in vivo is essential
for understanding TGF-β-mediated tumor evasion, we per-
formed a comprehensive analysis of TGF-β-responsive genes
in T cells. Focusing on CD8+ T cells, we have identified the
cytotoxic mediators perforin, GzmA, GzmB, IFNγ, and FasL as
five critical TGF-β target genes, collectively referred to here as
the cytotoxic program. The extent of the induction of these five
genes upon T cell stimulation and the extent of their repression
by TGF-β in our experiments varied with different in vitro and
in vivo conditions. However, repression of all or even part of
these genes would limit CTL-mediated tumor clearance. Regu-
lation of some of these genes was noted in early studies of T
cell lines (Genestier et al., 1999; Inge et al., 1992; Smyth et al.,
1991) or as part of a general effect of TGF-β on T cell develop-
ment in vitro (Bonig et al., 1999). We show that the expression
of these genes is inhibited by TGF-β independently of a block
in CD8+ T cell proliferation or activation, and it involves a se-
lective inhibition of the CTL cytotoxic program both in vitro and
in vivo.
We provide evidence that the effect of TGF-β on cytotoxicCANCER CELL : NOVEMBER 2005gene responses occurs with the direct involvement of the Smad
signaling pathway. We identified a TGF-β-responsive region in
the GzmB promoter, which requires an intact ATF1/CREB bind-
ing site. Strikingly similar to another ATF family member and
TGF-β target gene, ATF3, we found that ATF1 and CREB are
both induced by TGF-β in the presence of CHX. As in the case
of TGF-β-induced ATF3 cooperating with Smads to repress Id1
in epithelial cells (Kang et al., 2003), TGF-β-induced ATF1 and
CREB may cooperate with Smads to repress GzmB and IFNg
in T cells. Such self-enabled gene responses have been de-
scribed in other TGF-β-regulated processes from Drosophila to
humans (Massagué et al., 2005). However, it should be noted
that ATF1 and CREB may be only part of the mechanism medi-
ating Smad-dependent repression of these genes in T cells.
ATF family members can act as either transcriptional activa-
tors or repressors, depending on their binding partners (Hai
and Hartman, 2001). Specifically in T cells, the ATF1 family has
been implicated in the repression of various target genes (Penix
et al., 1996; Powell et al., 1999). We have shown that Smad2/3377
A R T I C L Eand ATF1 rapidly bind to the promoter region of at least two
genes in this program, GzmB and IFNg, in response to TGF-β.
TGF-β-dependent binding of Smads to a TGF-β-responsive
gene promoter and concomitant binding of a Smad-interacting
factor to an adjacent site are well-established criteria for direct
involvement of the Smad pathway in TGF-β target gene regula-
tion (Massagué et al., 2005).
siRNA-mediated knockdown of ATF1 and CREB in CTLL-2
cells demonstrated a partial loss of TGF-β-mediated repression
of GzmB. The residual repression of GzmB by TGF-β suggests
either that the knockdown levels attained with these oligonu-
cleotides were not sufficient to completely abrogate repression
by TGF-β or that there may be additional inputs by TGF-β on
the GzmB promoter, similar to several other well-characterized
TGF-β target genes (Massagué et al., 2005). Further analysis is
required to determine whether alternative Smad cofactors are
involved in repression of GzmB. However, RNAi-mediated de-
pletion of Smad2 and Smad3 causes a block in TGF-β-medi-
ated gene repression, indicating that repression of GzmB by
TGF-β is entirely a Smad-dependent effect. While further analy-
sis is required to fully characterize GzmB and IFNg as TGF-β-
responsive genes, it is interesting that TGF-β appears to coor-
dinate the repression of at least these two cytotoxic genes via
ATF1-Smad or CREB-Smad complexes in T lymphocytes.
TGF-β represses the cytotoxic programs, independent
of CD8+ T cell activation or growth inhibition
TGF-β can inhibit the expression and production of IL-2 by T
cells (McKarns et al., 2004). This effect is confirmed by our
transcriptomic profiling showing repression of IL-2 by TGF-β in
primary mouse T cells ex vivo, as well as our observation that
TGF-β inhibits IL-2 production and IL-2-mediated T cell prolif-
eration in these cells. However, by exposing these cells to ex-
ogenous IL-2 and thus bypassing the block of cell proliferation,
we have been able to clearly separate the antimitogenic effect
of TGF-β from its effects on the cytotoxic program. In addition,
TGF-β can rapidly (within 4 hr) downregulate GzmB and per-
forin expression in the IL-2-dependent T cell line CTLL-2,
which precedes growth inhibition by 20 hr, further highlighting
the independence of the two TGF-β-regulated pathways. Fur-
thermore, our analysis indicates that TGF-β does not alter the
overall activation profile of CD8+ T cells, as defined by the cell
surface markers CD69, CD44, and CD62L. Consistent with
these results, we observed no defect in CD8+ T cell activation
upon challenge with TGF-β-producing tumors in vivo. These
observations suggest that the CD8+ T cells in vivo undergo
proper development in the presence of tumor-derived TGF-β
but fail to activate cytotoxic gene expression.
However, as analyzed with the OVA antigen-MHC class I tet-
ramer system, the proportion of tumor-specific T cells was in-
creased when we neutralized tumor-associated TGF-β with a
TGF-β trap in our mouse model. This suggests that, similar to
in vitro observations, TGF-β regulates both the clonal expan-
sion of CD8+ T cells and CD8+ T cell cytotoxicity in vivo. Inhibi-
tion of T cell proliferation and repression of the cytotoxic gene
program in T cells are therefore two distinct effects, which, to-
gether, would ultimately favor tumor progression.
TGF-β blockade restores cytotoxic functions
in tumor-specific T cells
The ability to identify antigen-specific T cells using tetramers
of recombinant MHC class I bound to the antigenic peptide378has enormously facilitated the analysis of T cell biology under
tumor and pathogen challenges (Appay and Rowland-Jones,
2002; Xu and Screaton, 2002). We have combined tetramer
technology with T cell profiling to identify the molecular signa-
ture regulated by TGF-β, specifically in antigen-reactive T cells
in vivo. Our experiments using the EL4-OVA-soluble TβR-II
system demonstrate that systemic neutralization of TGF-β pro-
tects the tumor-specific activity of CTLs. The ability to recog-
nize and clear EL4-OVA tumor cells in this model system is
linked to increased expression of perforin, GzmA, GzmB, and
IFNγ but not FasL. The Fas-FasL pathway regulates the pri-
mary immune response through activation-induced cell death
(AICD). TGF-β1−/− T cells have increased surface levels of
FasL, suggesting that regulation of this pathway by TGF-β may
be critical for maintaining T cell homeostasis (Wahl et al., 2000).
Since neutralization of TGF-β in vivo does not alter FasL ex-
pression on antigen-specific CTLs, we conclude that Fas-FasL
pathway does not play an essential role in this in vivo tumor
clearance model.
The role of perforin and IFNγ in tumor clearance has been
demonstrated using perforin- and IFNγR1-deficient mice (Street
et al., 2001). However, the essential roles of GzmA and GzmB
in tumor clearance in vivo have not been consistently docu-
mented (Pardo et al., 2002b; Trapani and Sutton, 2003). Studies
have indicated that the nature and quality of the target cell may
dictate the requirement for each respective granzyme (Pardo
et al., 2002a). In addition, it is becoming increasingly evident
that the background strain of the mice plays a critical role in
determining which granzymes mediate tumor clearance in vivo
(Pardo et al., 2002b). While perforin-deficient mice are highly
susceptible to EL4 tumor challenge, GzmAxGzmB doubly defi-
cient mice have not been described. Although the individual
effector contributions are not detailed, neutralization of TGF-β
activity in vivo leads to restoration of a cytotoxic gene program,
which, collectively, would contribute to EL4 tumor clearance.
We also show that T cells that have suffered inhibition by
TGF-β can have their proliferation and cytolytic functions re-
stored upon removal of TGF-β and stimulation with IL-2. In
contrast, IL-15, a cytokine in the same γc family as IL-2 in-
volved in regulation of CD8+ T cell development and effector
function (Schluns and Leofrancois, 2003), could partially res-
cue proliferation but could not restore cytotoxic gene expres-
sion in T cells pretreated with TGF-β. These results suggest
that, following TGF-β treatment, IL-2 can rescue overall CD8+
T cell growth and effector functions, while IL-15 rescues only
CD8+ T cell expansion. Thus, the immunosuppressive effects
of TGF-β are reversible, and treatment with IL-2 is capable of
restoring CTL effector function in vitro. Neutralization of TGF-β
in vivo may not only allow new tumor-specific T cells to de-
velop, but these cells may also produce enough IL-2 to rescue
CTL effector functions.
The ultimate goal of cancer immunotherapy is to restore or
enhance the ability of tumor antigen-specific T cells to recog-
nize and eliminate tumor cells in vivo (Blattman and Greenberg,
2004). The paradoxical effects of TGF-β on the tumor cell itself
are already well documented, but only recently have the effects
of TGF-β on the host immune response been appreciated (Woj-
towicz-Praga, 2003). Therapies that target the TGF-β signaling
pathway in tumor cells, such as receptor kinase inhibitors and
TGF-β-neutralizing proteins, are currently in various stages of
clinical development (reviewed in (Dumont and Arteaga [2003];CANCER CELL : NOVEMBER 2005
A R T I C L EYingling et al. [2004]). Our studies suggest that neutralization
of the effects of TGF-β on T cells in vivo can restore critical
cytotoxic gene responses involved in tumor clearance. A better
understanding of the effects of TGF-β on the immune system
seems warranted so that new therapies will more comprehen-
sively address the role of TGF-β in cancer development.
Experimental procedures
T cell activation assays
CD4+/CD8+ or CD8+ T cells were purified from mouse spleens using MACS
magnetic bead cell sorting (Miltenyi Biotec) and activated with plate bound
0.25 g/ml antiCD3 plus soluble antiCD28 in the presence or absence of
100 pM TGF-β1 (R & D Systems) typically for 24 hr. Growth inhibition assays
were performed as previously described (Chen et al., 2001). RNA was ex-
tracted from T cells and Northern analysis was performed as previously
described (Chen et al., 2002). The GzmA, GzmB, and perforin cDNAs used
as northern probes as well as antiGzmA and antiGzmB rabbit polyclonal
serum were gifts from Dr. T.J. Ley (WUSM). ELISA analysis (R & D Systems)
was performed in triplicate according to the manufacturer’s protocol.
Flow cytometry and tetramer analysis
For flow cytometry assays of in vitro-activated T cells, 1 × 106 cells were
stained with the following antibodies: antiCD3 (CALTAG Laboratories),
antiCD4, antiCD69, antiCD8α, and antiCD25 (BD Pharmingen). Background
levels were determined with isotype-matched control antibodies. Recombi-
nant H-2Kb tetramers bound to OVA-peptide SIINFEKL were produced by
the Microchemistry Facility and Tetramer Core Facility at MSKCC. Freshly
purified spleen cells were stained with H-2Kb tetramers for 30 min on ice
and surface stained with CD8, CD44, CD62L, CD69, and/or FasL antibod-
ies. Cells were then fixed and permeabilized with Cytofix/Cytoperm kit (BD
Pharmingen), followed by intracellular staining with GzmB, GzmA (BD Phar-
mingen), IFNγ (R & D Systems), or perforin (Kamiya Biochemicals) antibod-
ies. A minimum of 100,000 live events were collected in duplicate and ana-
lyzed with FloJo6.1 software. Each experiment was performed three times,
each with two mice.
Microarray expression analysis
RNA was harvested from primary CD90+ T cells activated for 24 hr as de-
scribed above, and each sample, in duplicate, was hybridized to an Affy-
metrix Mouse Genome U74Av2 Microarray (MSKCC Genomics Core). Com-
parative analysis between TGF-β-treated and untreated T cell samples was
performed using Microarray Suite 5.0 software. Expression changes of
more than 2.0-fold with p = 0.001 were scored as TGF-β target genes.
Cell lines
Mouse P815 mastocytoma cells, EL4 lymphoma cells, EL4-OVA (E.G7), and
CTLL-2 T cells were all purchased from ATCC and cultured accordingly.
CTLL-2 cells were supplemented with 0.5 ng/ml rIL-2 every 2 days.
Transcriptional assays and knockdown experiments
CTLL-2 cells were pretreated with 10 g/ml CHX for 1 hr, prior to treatment
with TGF-β for 4 hr. Mouse GzmB promoter constructs (−3000 and −662)
were obtained from Dr. M. Cross (University of Leipzig, Germany) or Dr.
T.J. Ley (−960/+74;). The −885/+74 and −794/+74 deletion mutants were
generated using internal primers and cloned into the pGL2 basic promoter.
Mutation of individual transcription factor sites within the −885/+74 GzmB
promoter was performed using the following primers, with the replaced nu-
cleotides underlined: MT ATF1, 5#-GCCAGCCAGCCAGTTTAAGCTTATC
ACCAAGT TAATC-3#; MT Oct1/Gata1, 5#-GCCAGTTTAACGTAATCTAGAA
GTTAATCGAGA-3#; and MT AML1a, 5#-GAGAGACA CCTCTAGATCTCT
GGCCAGC-3#. CTLL-2 cells were transfected via the Amaxa Nucleofection
System Buffer R (Program T-28) or Buffer T (Program K-17).
Mouse siRNA oligonucleotides were obtained from the HTS Core Facility.
Three sets of oligonucleotide pairs targeting each gene were tested, and
knockdown experiments were performed via nucleofection into CTLL-2
cells. Sense strand of the siRNA oligonucleotide sequences for ATF1,
CREB1, Smad2, and Smad3 are as follows, respectively: 5#-GCGUUACU
AAGUAUGUA AATT-3#, 5#-CCACCCUCAAGAAGUAAUCTT-3#, 5#-CCCACANCER CELL : NOVEMBER 2005GUAUUGCAGUACUAUTT-3#, and 5#-UCGCCACCUGACUCCUUGUTT-3#.
After 48 hr, cells were treated minus and plus TGF-β for 3 hr, and Northern
analysis was performed.
ChIP
Primary mouse T cells were activated as described above, minus and plus
100 pM TGF-β for 15 hr. ChIP assays were performed as previously de-
scribed (Seoane et al., 2002). The antibodies utilized were antiSmad 2/3,
antiATF1 (Santa Cruz), and antiCREB (Cell Signaling). The GzmB primer set
spans −930 to −585, and the IFNγ primer set utilized spans −366 to −16,
relative to the transcriptional start site.
Cytotoxicity and tumor rejection assays
Cytotoxicity assays against mouse P815 mastocytoma tumor cells were
performed as previously described (Heusel et al., 1994). Human TβR-II ecto-
domain construct was generated by insertion of stop codon after amino
acid 168 and cloned into a retroviral vector. The mTGF-β1 RNAi oligonucle-
otides were cloned into retrovial vector: sense, gatccc GGAGACGGAATACA
GGGCTttcaagagaAGCCCTGTATTCCGTCTCC; antisense, agcttttccaaaaa
GGAGACGGAATACAGGGCTtctcttgaaAGCCCTGTATTCC TCTCCggg. Ex-
pression of soluble TβR-II was determined by goat anti-human TβR-II im-
munoblot (R & D Systems).
Five C57Bl/6 mice per cohort per experiment were injected intraperitone-
ally with 2.5 × 106 EL4-pRS, EL4-shTGF-β1, EL4/EL4-OVA, or EL4/EL4-
OVA soluble TβR-II cells. Mice were observed for signs of tumor develop-
ment and sacrificed accordingly.
Supplemental data
Supplemental Data include one table and can be found with this article
online at http://www.cancercell.org/cgi/content/full/8/5/369/DC1/.
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